Communiqués Cidara Therapeutics

Actions

CDTX

US1717572069

Marché Fermé - Nasdaq 22:00:00 06/01/2026			Varia. 5j.	Varia. 1 janv.
221,38 ^USD	+0,03%		-.--%	+0,22%

07/01	Cidara Therapeutics, Inc. annonce des changements au sein de son conseil d'administration, à compter du 7 janvier 2025	CI
07/01	Merck Sharp & Dohme LLC finalise l'acquisition de Cidara Therapeutics, Inc. (NasdaqCM:CDTX)	CI

Communiqués

24/11	Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations	AQ
17/11	Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX	BU
06/11	Cidara Therapeutics: Q3 Earnings Snapshot	AQ
06/11	Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results	AQ
28/10/25	Cidara Therapeutics to Participate in November Investor Conferences	AQ
24/10/25	Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10th ESWI Influenza Conference 2025	AQ
23/10/25	Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025	AQ
23/10/25	Cidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025	AQ
21/10/25	Cidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025	AQ
13/10/25	Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025	AQ
13/10/25	Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025	AQ
10/10/25	Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025	AQ
09/10/25	Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention	AQ
02/10/25	Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic	AQ
25/09/25	Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations	AQ
24/09/25	Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza	AQ
17/09/25	Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting	AQ
04/09/25	Cidara Therapeutics to Participate in September Investor Conferences	AQ
03/09/25	Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting	AQ
07/08/25	Cidara Therapeutics: Q2 Earnings Snapshot	AQ
07/08/25	Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results	AQ
24/07/25	Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025	AQ
08/07/25	Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics	AQ
02/07/25	Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
01/07/25	Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	AQ